Given that more than 90% of clinical specimens of pancreatic duct adenocarcinoma possess mutant K-ras, the effect of SOX2 downregulation by 6-MITC and I7557 in PANC-1 cells may have potential for further preclinical investigation. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.